Hippocratic AI
Hippocratic AI develops a safety-focused Large Language Model for healthcare, designed to improve health outcomes and increase care accessibility.
Secondary Market Price
Secondary Market Price
How Hippocratic AI Measures Up
To help you manage your Hippocratic AI equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Hippocratic AI's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Hippocratic AI Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Hippocratic AI's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Hippocratic AI is a company developing a safety-focused Large Language Model (LLM) specifically for the healthcare industry. The company is currently deploying its AI agents in collaboration with healthcare partners to assist with tasks such as patient scheduling, improving medication adherence, and managing chronic care. Founded in 2023 and based in Palo Alto, California, Hippocratic AI was co-founded by CEO Munjal Shah along with a team of physicians, hospital administrators, and AI researchers from institutions including Johns Hopkins, Stanford, Microsoft, and Google.
The company has raised a total of $278 million in funding, backed by investors such as Andreessen Horowitz, General Catalyst, Kleiner Perkins, and NVIDIA’s NVentures. Recent collaborations highlight the application of its technology in real-world settings. For instance, with Northwestern Medicine, the company's agents helped schedule patients for unfilled radiology appointments. At University Hospitals, the technology was used to support medication adherence and clarify instructions for patients. Another partnership with Medical Mutual resulted in a 360% increase in access to help for its chronic care population.
- General Catalyst
- Andreessen Horowitz
- Kleiner Perkins
- Avenir Growth
- CapitalG
- Premji Invest
- NVIDIA NVentures
- SV Angel
- Universal Health Services
- WellSpan Health
- Cincinnati Children's Hospital Medical Center
- Memorial Hermann Health System
- Greycroft
- Leo Shapiro of 7Wire Ventures
- John Doerr
- Rick Klausner
- Co-Founder, Munjal Shah
- Co-Founder, Vishal Parikh
- Co-Founder, Meenesh Bhimani
- Co-Founder, Subho Mukherjee
- Co-Founder, Saad Godil
- Co-Founder, Alex Miller
- Co-Founder, Kim Parikh
- Co-Founder, Debajyoti Datta
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Hippocratic AI worth joining?
Deciding to join any startup involves weighing the role, culture, and the total compensation package. A key part of that package is your equity, and understanding its potential future value is crucial for making an informed decision.
What should I do with my Hippocratic AI stock?
Managing private company stock requires a strategy for exercising options and planning for taxes to maximize its value. Platforms like Prospect offer tools to help you create an optimized plan for your equity.
Can you sell Hippocratic AI stock?
As a private company, Hippocratic AI stock is not publicly traded, so selling shares is typically limited to company-approved tender offers or secondary market sales. Tools exist to help you navigate these events and determine how many shares to sell for optimal tax outcomes.
How can I find the value of my Hippocratic AI stock?
The value of private stock is determined by the company's 409A valuation and investor sentiment, which can be tracked through secondary market prices. To forecast your equity's potential future worth, you can use predictive modeling tools that analyze data similar to what venture capitalists use.
What is Hippocratic AI's equity worth?
A private company's equity worth is based on its most recent valuation, often determined during a funding round or a 409A valuation. You can use financial modeling platforms to project your personal stake's potential value under various future scenarios.
What is Hippocratic AI's stock ticker symbol?
Hippocratic AI is a private company and does not have a stock ticker symbol, as those are assigned only when a company lists on a public stock exchange. Until an IPO occurs, its shares are not traded publicly.
Can I buy or sell Hippocratic AI stock?
Since Hippocratic AI is a private company, its stock is not available for purchase on public markets, and selling is restricted to specific liquidity events like tender offers. Employees with stock options can "buy" shares by exercising them according to their grant agreement.
What is the criteria to buy or invest in Hippocratic AI stock?
Investing in a private company like Hippocratic AI is typically restricted to employees receiving equity compensation or accredited investors participating in organized funding rounds. The general public cannot buy shares until the company undergoes an Initial Public Offering (IPO).
